GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (TSX:ONC) » Definitions » 3-Year ROIIC %

Oncolytics Biotech (TSX:ONC) 3-Year ROIIC % : 4,183.30% (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Oncolytics Biotech 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Oncolytics Biotech's 3-Year ROIIC % for the quarter that ended in Dec. 2023 was 4,183.30%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Oncolytics Biotech's 3-Year ROIIC % or its related term are showing as below:

TSX:ONC's 3-Year ROIIC % is ranked better than
98.97% of 1358 companies
in the Biotechnology industry
Industry Median: -13.43 vs TSX:ONC: 4183.30

Oncolytics Biotech 3-Year ROIIC % Historical Data

The historical data trend for Oncolytics Biotech's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech 3-Year ROIIC % Chart

Oncolytics Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -50.21 870.25 -686.61 78.29 4,183.30

Oncolytics Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 4,183.30 - - -

Competitive Comparison of Oncolytics Biotech's 3-Year ROIIC %

For the Biotechnology subindustry, Oncolytics Biotech's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncolytics Biotech's 3-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's 3-Year ROIIC % falls into.



Oncolytics Biotech 3-Year ROIIC % Calculation

Oncolytics Biotech's 3-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -33.9092685 (Dec. 2023) - -25.459 (Dec. 2020) )/( 1.312 (Dec. 2023) - 1.514 (Dec. 2020) )
=-8.4502685/-0.202
=4,183.30%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Oncolytics Biotech  (TSX:ONC) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Oncolytics Biotech 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncolytics Biotech Business Description

Traded in Other Exchanges
Address
322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.
Executives
Angela Frances Holtham Director
Deborah Brown Director
Bernd Robert Seizinger Director
Matthew Coffey Director, Senior Officer
Kirk Look Senior Officer

Oncolytics Biotech Headlines

No Headlines